Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRIT 3 in chronic myeloid leukaemia
ISRCTN60655195Phase 3Terminated
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- Sep 2013
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of imatinib, nilotinib and ponatinib in chronic myelogenous leukemia (CML) (2 arms), sponsored by Newcastle Hospitals NHS Foundation Trust. Primary endpoint: Major molecular response at 3 years. Started Sep 2013; status: terminated.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on ISRCTN60655195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN60655195.